Literature DB >> 3768529

The L4F3 antigen is expressed by unipotent and multipotent colony-forming cells but not by their precursors.

R G Andrews, M Takahashi, G M Segal, J S Powell, I D Bernstein, J W Singer.   

Abstract

Antibody L4F3 is a murine monoclonal antibody that recognizes an antigen expressed on in vitro colony-forming cells, including virtually all CFU-GM, CFU-Meg, BFU-E, and CFU-Mix. In the present study we examined whether cells that do not express the L4F3 antigen include precursors of hematopoietic colony-forming cells. Colony-forming cells were depleted from marrow by treatment with L4F3 and complement. The remaining cells generated CFU-GM, BFU-E, and CFU-Mix when cultured in the presence of irradiated adherent cell layers from long-term marrow cultures. Marrow cells not expressing the L4F3 antigen, which were separated by cell-sorting techniques, were depleted of colony-forming cells but nevertheless generated CFU-GM when cultured over irradiated adherent cell layers. These data suggest that there are marrow precursors that do not express the L4F3 antigen and that give rise to colony-forming cells of multiple types. Negative selection techniques should allow the enrichment of these precursors of colony-forming cells, thereby enabling direct studies of these immature stem cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3768529

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  24 in total

Review 1.  Acute myeloid leukemia stem cells and CD33-targeted immunotherapy.

Authors:  Roland B Walter; Frederick R Appelbaum; Elihu H Estey; Irwin D Bernstein
Journal:  Blood       Date:  2012-01-27       Impact factor: 22.113

Review 2.  Molecular characterization of CD34+ human hematopoietic progenitor cells.

Authors:  W Knapp; H Strobl; C Scheinecker; C Bello-Fernandez; O Majdic
Journal:  Ann Hematol       Date:  1995-06       Impact factor: 3.673

Review 3.  Immunotherapy prospects for acute myeloid leukaemia.

Authors:  A J Barrett; K Le Blanc
Journal:  Clin Exp Immunol       Date:  2010-05-31       Impact factor: 4.330

4.  Antigen CD34+ marrow cells engraft lethally irradiated baboons.

Authors:  R J Berenson; R G Andrews; W I Bensinger; D Kalamasz; G Knitter; C D Buckner; I D Bernstein
Journal:  J Clin Invest       Date:  1988-03       Impact factor: 14.808

Review 5.  Immunotherapy for acute myeloid leukemia.

Authors:  Joseph G Jurcic
Journal:  Curr Oncol Rep       Date:  2005-09       Impact factor: 5.075

6.  Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia.

Authors:  David C Taussig; Daniel J Pearce; Catherine Simpson; Ama Z Rohatiner; T Andrew Lister; Gavin Kelly; Jennifer L Luongo; Gwenn-Aël H Danet-Desnoyers; Dominique Bonnet
Journal:  Blood       Date:  2005-08-30       Impact factor: 22.113

Review 7.  What happened to anti-CD33 therapy for acute myeloid leukemia?

Authors:  Joseph G Jurcic
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

Review 8.  Basic and clinical immunology of Siglecs.

Authors:  Stephan von Gunten; Bruce S Bochner
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

9.  Treatment of acute myeloid leukemia cells in vitro with a monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressed.

Authors:  I D Bernstein; J W Singer; R G Andrews; A Keating; J S Powell; B H Bjornson; J Cuttner; V Najfeld; G Reaman; W Raskind
Journal:  J Clin Invest       Date:  1987-04       Impact factor: 14.808

Review 10.  Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia.

Authors:  Akihiro Takeshita
Journal:  Int J Hematol       Date:  2013-05-26       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.